Viking Therapeutics [VKTX] vs Vertex [VRTX] Detailed Stock Comparison

Viking Therapeutics Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Viking Therapeutics Inc. wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 13 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Viking Therapeutics Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) -10.27 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 5.89 5.92 Viking Therapeutics Inc.
Debt-to-Equity Ratio 0.02 10.91 Viking Therapeutics Inc.
PEG Ratio -0.03 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -7.85 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 0.00% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -47.34% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -30.28% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-278.69M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 22.16% 1.24% Viking Therapeutics Inc.
Price-to-Sales Ratio (TTM) N/A 9.22 N/A
Enterprise Value $3.08B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio N/A 8.83 N/A
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-3.19 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.82 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 21.90% 1.78% Vertex Pharmaceuticals Inc.

Viking Therapeutics Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

VKTX
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Viking Therapeutics Inc.0.14%-7.36%-7.65%-8.14%-17.17%-17.19%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Viking Therapeutics Inc.22.16%46.95%522.43%2,157.93%259.78%259.78%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Viking Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricVKTXVRTX
Market Information
Market Cap i$3.80B$109.45B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i2,079,1751,057,061
90 Day Avg. Volume i2,295,0421,272,097
Last Close$29.33$428.34
52 Week Range$22.96 - $43.15$362.50 - $507.92
% from 52W High-32.03%-15.67%
All-Time High$99.41 (Feb 26, 2024)$519.88 (Nov 04, 2024)
% from All-Time High-70.50%-17.61%
Growth Metrics
Quarterly Revenue GrowthN/A0.10%
Quarterly Earnings GrowthN/A0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i0.00%0.40%
Return on Equity (TTM) i-0.47%0.23%
Debt to Equity (MRQ) i0.0210.91
Cash & Liquidity
Book Value per Share (MRQ)$5.57$73.49
Cash per Share (MRQ)$6.11$26.01
Operating Cash Flow (TTM) i$-278,684,992$3.63B
Levered Free Cash Flow (TTM) i$-160,217,744$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Viking Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricVKTX (Apr 26, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-10.2728.40
Forward P/E i-7.3519.95
PEG Ratio i-0.030.88
Price to Sales (TTM) iN/A9.22
Price to Book (MRQ) i5.895.92
Market Capitalization
Market Capitalization i$3.80B$109.45B
Enterprise Value i$3.08B$105.96B
Enterprise Value Metrics
Enterprise to Revenue iN/A8.83
Enterprise to EBITDA i-7.8521.78
Risk & Other Metrics
Beta i0.820.37
Book Value per Share (MRQ) i$5.57$73.49

Financial Statements Comparison: Viking Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVKTX (2025)VRTX (2025)
Revenue/Sales i012.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i-13.8%
Gross Profit iN/A10.35B
Gross Margin i-86.2%
Research & Development i344.96M4.04B
Operating Income (EBIT) i-393.34M4.55B
Operating Margin i-37.9%
EBITDA i-392.97M5.25B
EBITDA Margin i-43.7%
Pre-Tax Income i-359.64M4.64B
Pre-Tax Income % of Revenue i-38.7%
Income Tax iN/A690.00M
Income Tax % of Revenue i-5.7%
Net Income (Profit) i-359.64M3.95B
Profit Margin i-32.9%

Balance Sheet & Liquidity Metrics

MetricVKTX (2025)VRTX (2025)
Cash & Equivalents i165.81M5.08B
Total Current Assets i715.60M11.20B
Total Current Assets % of Revenue i-93.3%
Total Current Liabilities i76.67M3.86B
Total Current Liabilities % of Revenue i-32.2%
Long-Term Debt i01.95B
Long-Term Debt % of Revenue i-16.3%
Total Shareholders Equity i639.06M18.67B
Retained Earnings i-847.55M13.56B
Retained Earnings % of Revenue i-113.0%
Property, Plant & Equipment i01.56B

Cash Flow Statement Comparison

MetricVKTX (2025)VRTX (2025)
Operating Cash Flow i-270.32M3.77B
Operating Cash Flow % of Revenue i-31.4%
Capital Expenditures iN/A-437.60M
Free Cash Flow i-278.69M3.19B
FCF Margin i-26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricVKTXVRTX
Shares Short i24.01M4.02M
Short Ratio i9.732.80
Short % of Float i21.90%1.78%
Shares Outstanding i114.79M253.99M
Float Shares i112.74M253.24M
% Held by Insiders i2.81%0.21%
% Held by Institutions i63.11%97.60%
% Held by Public i34.08%2.19%

Dividend Analysis & Yield Comparison: Viking Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricVKTXVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A